Matrix-Metalloproteinase-2 Predicts Arteriovenous Fistula Failure in Hemodialysis Patients
| Autor: | Crina Rusu, Ioan Mihai Paţiu, Dan Ştefan Vlăduţiu, Laura Pop, Diana Moldovan, Dacian Tirinescu, Cosmina Ioana Bondor, Alina Potra, Ciprian Tomuleasa, Ina Maria Kacso |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Fistula 030232 urology & nephrology Vascular access Arteriovenous fistula Hematology 030204 cardiovascular system & hematology Matrix metalloproteinase medicine.disease Pathophysiology Surgery 03 medical and health sciences Stenosis 0302 clinical medicine Nephrology Internal medicine Cardiology Medicine Hemodialysis business Dialysis |
| Zdroj: | Therapeutic Apheresis and Dialysis. 21:586-591 |
| ISSN: | 1744-9979 |
| Popis: | In hemodialysis patients the principal cause of arteriovenous fistula dysfunction is stenosis. Matrix-metalloproteinase-2 is implicated in the pathophysiological mechanism of stenosis development. Our study tried to assess the clinical impact of this protease on arteriovenous fistula survival. Seventy-nine prevalent dialysis patients with functional arteriovenous fistulas were included in the study. The presence of stenosis and the serum levels of matrix-metalloproteinase-2 were determined at the beginning of the study. The patency of the arteriovenous fistulas was followed- up for two years. In multivariate regression; matrix-metalloproteinase-2 was a significant predictor of vascular access loss (HR = 1.104, 95%CI 1.033-1.179, P = 0.003). Patients with a level of matrix-metalloproteinase-2 lower than 50 ng/mL had a better survival of the arteriovenous fistulas. Matrix-metalloproteinase-2 was an even stronger predictor of fistula failure in the stenosis group (HR = 1.076, 95%CI 1.027-1.127, P = 0.002). In our study matrix-metalloproteinase-2 has a predictive value for arteriovenous fistula failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text